Adrian Raiche, Ph.D. Named as Director of Formulation Development at Coldstream Laboratories, Inc.
Coldstream and Goodwin Biotechnology will co-exhibit at the World ADC Summit in San Francisco, CA, from October 14th to 17th. Please meet us at Booth #13 to discuss your cytotoxic antibody drug conjugation needs.
LEXINGTON, KY--(Marketwired - Sep 24, 2013) - Coldstream Laboratories, Inc., a provider of sterile drug product development and manufacturing services, has announced that they have been awarded a 5-year contract with the National Cancer Institute ("NCI") under solicitation number N02CM37007-11 (contract# HHSN261201300031I) entitled "Development and Production of Parenteral Dosage Forms for Clinical Studies."
Pamela Savoy Added as Director of Business Development at Coldstream Laboratories, Inc.
Christopher A. Verbicky, Ph.D., MBA, will be attending the “6th Product and Pipeline Enhancement for Generics Conference” in this week in Washington, D.C. The event will take place at the Sheraton Crystal City Hotel July 23 – 25, 2013.
Plantation, Florida and Lexington, Kentucky-- Goodwin Biotechnology, Inc. (GBI) and Coldstream Laboratories, Inc. have established a collaboration for developing and manufacturing high-potency, highly cytotoxic materials (e.g., small molecules, protein toxins, cytotoxic antibody drug conjugates, and other bioconjugates).
Photo Caption: Equinext’s President and CEO, Eric Hauck, with Eric Smart, President and CEO of Coldstream Laboratories in Coldstream’s sterile manufacturing facility.
Representatives from Coldstream Laboratories will be attending Informex 2013 in Anaheim, CA. The event will take place at the Anaheim Convention Center February 19 - 22, 2013.
In order to effectively develop a lyophilization cycle, it is important to understand the glass transition temperature (through Differential Scanning Calorimetry “DSC”) and collapse temperature (through Freeze-Drying Microscopy “FDM”) of the formulation between the liquid, glassy, and frozen states. These values will help define the maximum product temperature that the product can achieve during primary drying in order to prevent collapse or melt back of the product due to incomplete sublimation of unbound moisture and/or solvent. This should happen prior to the ramp to secondary drying with final removal of the bound moisture and/or solvent.
LEXINGTON, KY (Marketwire - October 29, 2012) – Eric W. Smart has been named the new President and CEO of Coldstream Laboratories Inc., the largest sterile pharmaceutical manufacturing facility in Kentucky.
© 2013 Coldstream LabsAll rights reserved